Trial Profile
A Clinical Study of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Patients With Advanced Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Anti MUC1 CAR T cell/PD-1 knockout engineered T cell therapy Guangzhou Anjie Biomedical Technology (Primary) ; PD-1 knockout T-cells (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 25 Oct 2018 New trial record